A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020

ROS1 fusion–positive (ROS1+) NSCLC was discovered in 2007, the same year as the discovery of ALK-positive (ALK+) NSCLC but has trailed ALK+ NSCLC in terms of development. There seems to be a differential response to ROS1 inhibitors, which depend on fusion partners (CD74, SLC34A2, or SDC4); thus, kno...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Sai-Hong Ignatius, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474457/
https://www.ncbi.nlm.nih.gov/pubmed/34589944
http://dx.doi.org/10.1016/j.jtocrr.2020.100048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474457/
https://www.ncbi.nlm.nih.gov/pubmed/34589944
http://dx.doi.org/10.1016/j.jtocrr.2020.100048

Ejemplares similares